Bao Ting, Davidson Nancy E
The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, 1650 Orleans Street, Baltimore, Maryland 21231, USA.
Adv Surg. 2008;42:249-60. doi: 10.1016/j.yasu.2008.03.002.
Gene expression profiling is enabling scientists to understand the heterogeneous nature of breast cancer on a genomic level. Several gene expression profiles for breast cancers have emerged in the initial studies and appear to be generally concordant in their ability to predict poor outcome. Of these profiles, the Oncotype Dx and Mammaprint assays are the best validated and are commercially available. Their role in clinical practice is being refined through ongoing clinical trials. Other efforts are directed at determining host factors that might help identify prognosis as well as response and toxicity of therapy. It is expected that availability of these types of analyses will only increase in the future. It will be imperative that such assays be well validated and have implications for how to modify care for the individual patient.
基因表达谱分析使科学家能够在基因组水平上了解乳腺癌的异质性。在最初的研究中出现了几种乳腺癌的基因表达谱，并且它们在预测不良预后的能力上似乎总体一致。在这些谱中，Oncotype Dx和Mammaprint检测是经过最佳验证且可商购的。它们在临床实践中的作用正在通过正在进行的临床试验得到完善。其他研究致力于确定可能有助于识别预后以及治疗反应和毒性的宿主因素。预计这类分析在未来只会越来越多。至关重要的是，此类检测要经过充分验证，并对如何针对个体患者调整治疗具有指导意义。
